Vitality Watch

Dossier pubmed preclinical 06-oct-2026
Animal model, organoid, or cell-culture result — not yet human

Resveratrol protects primary hepatocytes against senescence induced by endogenous toxic metabolites.

Key claim: Resveratrol at 5 µM reverses senescence induced by endogenous liver toxins (SILT) in primary human and porcine hepatocytes and partially restores albumin production and urea synthesis in a species- and function-dependent manner.

Abstract

Liver dysfunction rates increase markedly with ageing causing the plasma concentrations of toxic endogenous metabolites to rise. We demonstrated that brief exposure of HepG2 cells in vitro to a liver-derived toxic metabolite cocktail triggers a distinct state of cellular senescence termed senescence induced by liver toxins (SILT). SILT combines classical features of senescence (loss of proliferative capacity, proinflammatory changes, senescence associated β- galactosidase reactivity and cyclin dependent kinase inhibitor upregulation) with a broader loss of essential hepatocyte functions. Immortalised cell lines are valuable models for primary hepatic function but also show important physiological differences. We have extended our analysis to primary hepatocytes and have found that both human and porcine liver cells undergo SILT in vitro when exposed to the concentrations of endogenous toxins typical of liver disease. As in HepG2 cells, SILT in primary hepatocytes was accompanied by loss of albumin production (as measured by ELISA) and urea synthesis (measured biochemically) but was reversible by 5µM resveratrol in a species- and function-dependent manner. Deeper transcriptomic profiling of SILT revealed the activation of stress and inflammatory pathways combined and repression of hepatocyte metabolic programmes. Gene Set Enrichment Analysis demonstrates that the SILT is present in vivo in multiple reference transcriptomic datasets derived from diseased, but not healthy liver. This is consistent with the presence of a population of SILT hepatocytes among the senescent cells found in the ageing organ in vivo. Thus, SILT may contribute to the ultimate failure of liver function which may potentially be delayed by resveratrol treatment.

Why this matters

SILT frames a distinct toxin-triggered hepatocyte senescence state separable from replicative, oxidative, or oncogene-induced senescence, giving the liver-aging arm of senescence biology a specific endogenous-metabolite trigger to work against. The functional readouts (albumin, urea) tie senescence reversal to hepatocyte-specific metabolic output rather than generic marker reduction, but the evidence is primary-cell only — no in vivo liver aging or human translation, and resveratrol’s track record of species- and context-dependent effects (including recent pro-aging signals in middle-aged C. elegans and senescent fibroblasts) complicates extrapolation.

Source

Link

Briefing card

Resveratrol protects primary hepatocytes against senescence induced by endogenous toxic metabolites.
Stage: preclinical · pubmed · 06-oct-2026

If you follow resveratrol research, this adds primary human hepatocyte data on toxin-driven senescence reversal — but still no in vivo liver outcome evidence.

Resveratrol at 5 µM reverses senescence induced by endogenous liver toxins (SILT) in primary human and porcine hepatocytes and partially restores albumin production and urea synthesis in a species- and function-dependent manner.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.mad.2026.112261

build build 880 · 2bcef25 · 2026-11-18